An Open-Label Study of ION-682884 in Patients With TTR Amyloidosis Who Have Completed a 24-Open Label Study of Inotersen for TTR Amyloidosis Cardiomyopathy
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Eplontersen (Primary)
- Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
- Focus Biomarker; Therapeutic Use
- 15 Apr 2021 New trial record